Advertisement
Advertisement
PRLD
Prelude Therapeutics Incorporated
0.83
USD+0.05
+6.94%
Aug 01, 15:58 UTC -4
Closed
After-Market
0.90
+0.07
+7.91%
Prelude Therapeutics Incorporated Profile
Info & Links
CEO
Krishna Vaddi
Headquarters
Wilmington, DE 19805, UNITED STATES
Industry
Sector
Website
Auditor
Ernst & Young LLP
Share holders
19
Employees
131
Prelude Therapeutics Incorporated Statistics
Valuation Measures
Market Capitalization2
50.81M
Enterprise Value
10.60M
Enterprise Value/EBITDA(ttm)
-0.08
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
--
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
50.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
-448.49%
Return on Equity(ttm)
--
Return on Invested Capital(ttm)
-92.64%
Return on Assets(ttm)
--
Income Statement
Revenue(ttm)
7.00M
Revenue Per Share(ttm)
0.12
Gross Profit(ttm)
7.00M
EBITDA(ttm)3
-141.21M
Net Income Available to Common(ttm)
-127.83M
Diluted EPS(ttm)
--
Share Statistics
Beta (5Y Monthly)
--
52-Week Change
-86.91%
S&P 500 52-Week Change
16.67%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
56.46M
Dividend Yield
--
Float4
--
% Held by Insiders
--
% Held by Institutions
--
Balance Sheet
Total Cash(mrq)
99.07M
Total Cash Per Share(mrq)
1.75
Total Debt(mrq)
53.00K
Total Debt/Equity(mrq)
0.05%
Current Ratio(mrq)
5.18%
Quick Ratio(mrq)
--
Book Value Per Share(mrq)
1.83
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.45
Free Cash Flow(ytd)
-34.28M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
- 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
- 2 Market Cap is calculated using total shares outstanding and the most recent share price.
- 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
- 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement